Alert Data News | Business | Companies | UK | Chemicals, Pharmaceuticals, Biotechnology

Smith & Nephew PLC

Tue, 07 Feb 2012 02:37:00 +0000

£95m costs to be cut - 770 worldwide Jobs Lost - Profits down to £537m
Smith & Nephew, which employs 11,000 people worldwide including 1,200 in the UK, is to save £95m in costs over the next two years by cutting around 770 administrative jobs.

AstraZeneca PLC

Mon, 06 Feb 2012 09:30:46 +0000

7,300 job losses - 2% fall in revenues - competitive pressures
AstraZeneca is reducing headcount by 7,300 across its operations after revenue fell 2% to £22.2bn. Revenue in Western Europe fell 11% due to increased competition from generic drugs. It is not known which sites will be affected by the job cuts. The restructuring is expected to reduce costs and increase flexibility in functional areas.

AstraZeneca PLC

Mon, 06 Feb 2012 08:00:05 +0000

Revenue down 2% - Profit down 4% - 61700 Employees
AstraZeneca reorted revenue for the full year was down 2% at constant exchange rates at $33,591 million. Strong double-digit sales growth for Crestor, Seroquel XR and Symbicort; Emerging Markets revenue increased by 10%. Revenue performance reflects the loss of nearly $2 billion of revenue from generic competition, as well as a further $1 billion lost to the impact of government price interventions. David Brennan is Chief Executive Officer

Byotrol Plc

Fri, 03 Feb 2012 15:00:11 +0000

New product launched with partner - Contract extended worth £300,000
Byotrol plc, the developer of anti microbial hygiene technologies, and partner Rentokil Initial Plc, have formally launched the UltraProtect range, powered by Byotrol, under a contract announced in July 2011. UltraProtect is a range of hand and surface sanitising products for commercial and public use, featuring a gel hand sanitiser, a foam hand sanitiser, and handy packs of hand and surface wipes. In addition, Byotrol has agreed terms for a six month extension of the Joint Development Agreement ('JDA') with their Fortune 150 partner company, for which Byotrol Consumer Products Limited will receive $300,000. Gary Millar is the Chief Executive of Byotrol Plc.

Mediwatch plc

Fri, 03 Feb 2012 08:00:05 +0000

Profits increased to £322,000 - improved product lines
Mediwatch Plc recorded significantly improved pre-tax profits of £322,000 for the year to October 2011 compared with £233,000 in 2010. The company expects to complete a number of projects in 2012 which will strengthen and update its product lines. An improved performance for 2012 and beyond is expected.

Tetenal Limited

Thu, 02 Feb 2012 09:33:42 +0000

Lease taken on warehouse - potential new jobs
Photographic paper and chemicals manufacturer Tetenal Ltd has taken a lease on a 16,000 sq ft warehouse in Leicestershire as part of its business expansion strategy. It is anticipated that jobs could be create at the new site.

GlaxoSmithKline PLC

Tue, 31 Jan 2012 12:00:02 +0000

Changes to Board - New Chairs appointed - Non-Executive Directors appointed and step down
GlaxoSmithKline plc has reported that Sir Crispin Davis, Sir Robert Wilson and Mr Larry Culp, currently members of the GSK Board, will not stand for re-election to the Board at the Annual General Meeting (AGM) taking place in 2013. Tom de Swaan will succeed Sir Crispin Davis as Chairman of the Remuneration Committee with effect from January 2013. Mr de Swaan has been a member of the Remuneration Committee since May 2009. Judy Lewent will succeed Tom de Swaan as Chair of the Audit and Risk Committee with effect from January 2013. Ms Lewent has been a member of the Audit and Risk Committee since April 2011. In addition, Sir Deryck Maughan will succeed Sir Robert Wilson as Senior Independent Non-Executive Director at the close of GSKs AGM in 2013. James Murdoch has also decided not to stand for re-election to the Board at GSKs AGM in 2012. Sir Christopher Gent is Chairman of GSK.

Synergy Health PLC

Tue, 31 Jan 2012 09:17:11 +0000

Revenue up 10% - Underlying Revenue up 11% - 4300 Employees
Swindon-based Synergy Health, which provides outsourced support services to health related markets, has recorded like-for-like sales for its third quarter up 10.8 per cent to £232.5m. Underlying revenues, excluding currency effects and prior year non-core business, were £229.5m, up 11.5 per cent for the three months ending 2 January.

Abbott Laboratories Limited

Fri, 27 Jan 2012 14:00:02 +0000

Business expansion - Sales rise by 4.1% - Seven new products launched
Healthcare company Abbott Laboratories Limited, has recorded a 4.1% rise in sales to $10.4 billion. New markets represented approximately 25% of total sales at $2.5 billion. The global company has a UK base in Maidenhaed, Berkshire. In 2011, Abbott continued to expand its business and launched several new products or indications across their Pharmaceuticals, Medical Products, Nutritionals and Diagnostics businesses. Miles D. White is Chairman and Chief Executive Officer of Abbot Laboratories Limited.

Ekf Diagnostics Limited

Fri, 27 Jan 2012 09:34:32 +0000

Revenue £21.6m - Earnings above expectation - Further gowth expected
EKF Diagnostics, the Penarth-based medical test kit company, has forecast strong organic growth for 2012 and could also make acquisitions. Unaudited revenues for the year to December 2011 were £21.6m and adjusted EBITDA earnings will be significantly ahead of market expectations.